Finanzen von Akari Therapeutics PLC (AKTX)AKTXAkari Therapeutics PLC

Evaluating the bottom line, Akari Therapeutics PLC maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -140.09%, provide a clear picture of how effectively AKTX converts its operational activities into shareholder value.

In the context of the broader market, AKTX competes directly with industry leaders such as NCEL and PLUR. With a market capitalization of $16.88M, it holds a leading position in the sector. When comparing efficiency, AKTX's gross margin of N/A stands against NCEL's N/A and PLUR's 58.51%. Such benchmarking helps identify whether Akari Therapeutics PLC is trading at a premium or discount relative to its financial performance.

The company has reported zero revenue in several quarters, with a net income of -14,455,000 USD in Q1 2026, highlighting significant financial challenges. The current ratio is low at 0.27, indicating potential liquidity issues.